keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer, non small cell lung cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/27922113/non-small-cell-lung-cancer-quantitative-phenotypic-analysis-of-ct-images-as-a-potential-marker-of-prognosis
#1
Jiangdian Song, Zaiyi Liu, Wenzhao Zhong, Yanqi Huang, Zelan Ma, Di Dong, Changhong Liang, Jie Tian
This was a retrospective study to investigate the predictive and prognostic ability of quantitative computed tomography phenotypic features in patients with non-small cell lung cancer (NSCLC). 661 patients with pathological confirmed as NSCLC were enrolled between 2007 and 2014. 592 phenotypic descriptors was automatically extracted on the pre-therapy CT images. Firstly, support vector machine (SVM) was used to evaluate the predictive value of each feature for pathology and TNM clinical stage. Secondly, Cox proportional hazards model was used to evaluate the prognostic value of these imaging signatures selected by SVM which subjected to a primary cohort of 138 patients, and an external independent validation of 61 patients...
December 6, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27919971/usefulness-of-18f-%C3%AE-methyltyrosine-pet-for-therapeutic-monitoring-of-patients-with-advanced-lung-cancer
#2
Kyoichi Kaira, Tetsuya Higuchi, Noriaki Sunaga, Yukiko Arisaka, Takeshi Hisada, Hideyuki Tominaga, Noboru Oriuchi, Takayuki Asao, Yoshihito Tsushima, Masanobu Yamada
BACKGROUND/AIM: L-[3-(18)F]-α-methyl tyrosine ((18)F-FAMT) positron emission tomography (PET) has a high specificity for detecting malignant lesions. However, the usefulness of therapeutic monitoring of (18)F-FAMT PET against advanced human neoplasms remains unclear. Here, we evaluated (18)F-FAMT PET clinical significance regarding therapy response and outcome after systemic chemotherapy in patients with advanced lung cancer, compared to (18)F-FDG PET. PATIENTS AND METHODS: All patients with untreated advanced lung cancer received (18)F-FAMT PET and (18)F-FDG PET before and 4 weeks after one cycle of chemotherapy...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27901069/molecular-profiling-of-circulating-tumour-cells-identifies-notch1-as-a-principal-regulator-in-advanced-non-small-cell-lung-cancer
#3
Javier Mariscal, Marta Alonso-Nocelo, Laura Muinelo-Romay, Jorge Barbazan, Maria Vieito, Alicia Abalo, Antonio Gomez-Tato, Casares de Cal Maria de Los Angeles, Tomas Garcia-Caballero, Carmela Rodriguez, Elena Brozos, Francisco Baron, Rafael Lopez-Lopez, Miguel Abal
Knowledge on the molecular mechanisms underlying metastasis colonization in Non-Small Cell Lung Cancer (NSCLC) remains incomplete. A complete overview integrating driver mutations, primary tumour heterogeneity and overt metastasis lacks the dynamic contribution of disseminating metastatic cells due to the inaccessibility to the molecular profiling of Circulating Tumour Cells (CTCs). By combining immunoisolation and whole genome amplification, we performed a global gene expression analysis of EpCAM positive CTCs from advanced NSCLC patients...
November 30, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27900059/expression-and-survival-significance-of-b-cell-specific-moloney-murine-leukemia-virus-integration-site-1-and-matrix-metalloproteinase-9-in-non-small-cell-lung-cancer
#4
Mingkui Mu, Yang Song, Bin Zhang
One of the main challenges in lung cancer research is identifying patients at high risk of progression and metastasis following surgical resection. In the present study, the prognostic significance of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) and matrix metalloproteinase-9 (MMP9) in non-small-cell lung cancer (NSCLC) was evaluated. BMI1 and MMP9 expression in tumors from 132 surgical NSCLC patients [squamous cell carcinoma (SCC), n=79; and adenocarcinoma (AD), n=53] was evaluated by immunohistochemistry...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899967/heteroplasmy-of-mutant-mitochondrial-dna-a10398g-and-analysis-of-its-prognostic-value-in-non-small-cell-lung-cancer
#5
Yuexiao Qi, Yuehua Wei, Qiaoli Wang, Hui Xu, You Wang, Anqi Yao, Hui Yang, Yan Gao, Fuxiang Zhou
Mitochondrial dysfunction is associated with pathogenic mitochondrial (mt)DNA mutations. The majority of mtDNA point mutations have a heteroplasmic status, which is defined as the coexistence of wild-type and mutated DNA within a cell or tissue. Previous findings demonstrated that certain mtDNA heteroplasmic mutations contribute to widely spread chronic diseases, including cancer, and alterations in the heteroplasmy level are associated with the clinical phenotype and severity of cancer. In the present study, the proportions of mutant mtDNA 10398G were assessed using amplification-refractory mutation system-quantitative polymerase chain reaction (PCR) assay in 129 non-small cell lung cancer (NSCLC) tissue samples...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27895734/periostin-and-tumor-stroma-interactions-in-non-small-cell-lung-cancer
#6
Ulrich Nitsche, Daniela Stangel, Zheng Pan, Anna Melissa Schlitter, Irene Esposito, Ivonne Regel, Susanne Raulefs, Helmut Friess, Jörg Kleeff, Mert Erkan
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-associated mortality globally. Interactions of the cancer cells with the tumor microenvironment are essential carcinogenic features for the majority of solid tumors, such as pancreatic cancer. The present study investigated the role of stromal activation in NSCLC and analyzed the surgical specimens of 93 patients by immunohistochemistry with regard to periostin (an extracellular matrix protein), α-smooth muscle actin (α-SMA; a marker of myofibroblasts) and cluster of differentiation 31 (CD31; a marker of endothelial cells), and the activated stroma index...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27893326/randomized-prospective-biomarker-trial-of-ercc1-for-comparing-platinum-and-nonplatinum-therapy-in-advanced-non-small-cell-lung-cancer-ercc1-trial-et
#7
Siow Ming Lee, Mary Falzon, Fiona Blackhall, James Spicer, Marianne Nicolson, Abhro Chaudhuri, Gary Middleton, Samreen Ahmed, Jonathan Hicks, Barbara Crosse, Mark Napier, Julian M Singer, David Ferry, Conrad Lewanski, Martin Forster, Sally-Ann Rolls, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, Allan Hackshaw
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#8
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27877226/rac1-overexpression-is-correlated-with-epithelial-mesenchymal-transition-and-predicts-poor-prognosis-in-non-small-cell-lung-cancer
#9
Yujuan Zhou, Qianjin Liao, Yaqian Han, Jie Chen, Zhigang Liu, Hang Ling, Jing Zhang, Wenjuan Yang, Linda Oyang, Longzheng Xia, Li Wang, Heran Wang, Lei Xue, Hui Wang, Bingqiang Hu
Objective: Ras-related C3 botulinum toxin substrate1(Rac1) and epithelial mesenchymal transition (EMT) are key therapeutic targets in cancer. We investigated the clinical significance of Rac1 and markers of EMT expression in non-small cell lung cancer (NSCLC), and their possible correlation with EMT phenotype. Methods: Immunohistochemistry was used to assess the expression of Rac1, Snail1, Twist1, N-cadherin (N-cad), Vimentin (Vim), and E-cadherin (E-cad) in 153 NSCLC paraffin-embedded specimens and 45 normal specimens adjacent to tumors...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27866518/-expression-of-lncrna-ak09398-and-relationship-with-prognosis-in-patients-with-small-cell-lung-cancer
#10
Bin Liu, Xiaoqin Liu, Ye Yang, Jun Ge, Jing Li
BACKGROUND: Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancer. The poor prognosis of SCLC patients is attributed to the early blood and lymph node metastasis. However, the mechanism of SCLC is still unclear. Recent studies show that LncRNA plays an important role in the development, metastasis, and apoptosis of tumor. Thus, the present study aimed to investigate the expression and clinical significance of LncRNA AK09398 in SCLC. METHODS: Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect the expression of LncRNA AK09398 in 118 cases of SCLC and non-cancerous tissues...
November 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27866514/-paraneoplastic-leukocytosis-and-thrombocytosis-as-prognostic-biomarkers-in-non-small-cell-lung-cancer
#11
Prajwal Boddu, Dana Villlines, Mebea Aklilu
BACKGROUND: Search for inexpensive laboratory markers have identified associations between blood counts and lung cancer outcomes. In this study, we evaluated the prognostic value of paraneoplastic leukocytosis (p-Leukocytosis) and paraneoplastic thrombocytosis (p-Thrombocytosis) in patients with non-small cell lung cancer (NSCLC). We also studied their relation to the expression of commonly detected molecular markers. METHODS: We conducted a retrospective chart review on 571 consecutive NSCLC patients over a 10 year period...
November 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27856179/exosomal-proteins-as-prognostic-biomarkers-in-non-small-cell-lung-cancer
#12
B Sandfeld-Paulsen, N Aggerholm-Pedersen, R Bæk, K R Jakobsen, P Meldgaard, B H Folkersen, T R Rasmussen, K Varming, M M Jørgensen, B S Sorensen
BACKGROUND: Use of exosomes as biomarkers in non-small cell lung cancer (NSCLC) is an intriguing approach in the liquid-biopsy era. Exosomes are nano-sized vesicles with membrane-bound proteins that reflect their originating cell. Prognostic biomarkers are needed to improve patient selection for optimal treatment. We here evaluate exosomes by protein phenotyping as a prognostic biomarker in NSCLC. METHODS: Exosomes from plasma of 276 NSCLC patients were phenotyped using the Extracellular Vesicle Array; 49 antibodies captured the proteins on the exosomes, and a cocktail of biotin-conjugated antibodies binding the general exosome markers CD9, CD81 and CD63 was used to visualise the captured exosomes...
October 21, 2016: Molecular Oncology
https://www.readbyqxmd.com/read/27835582/overexpression-of-b7-h3-correlates-with-aggressive-clinicopathological-characteristics-in-non-small-cell-lung-cancer
#13
Shanshan Wu, Xiangfei Zhao, Sudong Wu, Rui Du, Qi Zhu, Henghu Fang, Xinhong Zhang, Chunyang Zhang, Wei Zheng, Jihua Yang, Huasong Feng
Previous studies have investigated the prognostic significance of B7 homolog 3 (B7-H3) in non-small cell lung cancer (NSCLC), however, the results remain controversial. This study was aimed to determine the correlation between B7-H3 and survival as well as clnicalpathological characteristics in NSCLC using meta-analysis. We searched the electronic databases of PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) for relevant studies up to October 9, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the impact of B7-H3 on overall survival (OS)...
November 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27832750/metastasis-associated-in-colon-cancer-1-and-aldehyde-dehydrogenase-1-are-metastatic-and-prognostic-biomarker-for-non-small-cell-lung-cancer
#14
Lei Zhou, Lan Yu, Bo Zhu, Shiwu Wu, Wenqing Song, Xiaomeng Gong, Danna Wang
BACKGROUND: Tumor recurrence and metastasis are the most common reason for treatment failure. Metastasis-associate in colon cancer-1 (MACC1) has been identified as a metastatic and prognostic biomarker for colorectal cancer and other solid tumors. Aldehyde dehydrogenase 1 (ALDH1), a marker of cancer stem cells, is also associated with metastasis and poor prognosis in many tumors. However, the prognostic value of either MACC1 or ALDH1 in non-small cell lung cancer (NSCLC) is unclear. In this study, we explored the relationship between MACC1 and ALDH1 expression, as well as their respective associations with clinicopathological features, to determine if either could be useful for improvement of survival prognosis in NSCLC...
November 10, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27826583/weight-gain-as-a-surrogate-marker-of-longer-survival-in-advanced-non-small-cell-lung-cancer-patients
#15
COMMENT
Erkan Topkan
Weight loss (WL), as a key step of the irreversible and fatal cancer-related anorexia cachexia syndrome is present to some degree in 80% of non-small cell lung cancer (NSCLC) patients upon diagnosis which has been clearly proved to negatively alter patients' performance status, quality of life (QOL), response to treatment, and prognosis. However, WL is not a problem encountered only upon diagnosis but is also commonly reported during the course of aggressive chemotherapy, radiotherapy (RT) and particularly the concurrent chemoradiotherapy (C-CRT) which may further diminish QOL measures and clinical outcomes...
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27816968/diagnostic-and-prognostic-value-of-serum-periostin-in-patients-with-non-small-cell-lung-cancer
#16
Chun-Hua Xu, Wei Wang, Yong Lin, Li-Hua Qian, Xiu-Wei Zhang, Qing-Bo Wang, Li-Ke Yu
The periostin protein is expressed in a variety of human malignancies. The aim of this study was to explore the diagnostic and prognostic value of serum periostin levels in patients with non-small cell lung cancer (NSCLC). We measured serum periostin levels by ELISA in 296 NSCLC patients, 120 benign lung diseases (BLD) patients and 160 healthy controls. The levels of serum periostin in NSCLC patients were significantly elevated compared with those in healthy controls (P < 0.001) and BLD patients (P < 0...
November 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27794412/prediction-of-distant-recurrence-in-resected-stage-i-and-ii-lung-adenocarcinoma
#17
Beatrice Aramini, Christian Casali, Alessandro Stefani, Stefania Bettelli, Susanne Wagner, Zaina Sangale, Elisha Hughes, Jerry S Lanchbury, Antonino Maiorana, Uliano Morandi
OBJECTIVES: Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non-small-cell lung cancer remain under discussion. Pathological features are the main determinant of follow-up therapy but have limited ability to identify patients at risk of recurrence. Increasingly, molecular markers are incorporated into clinical decision-making, including measures of tumor growth. The CCP score is a quantitative, molecular measure of proliferation derived from the RNA expression of 31 cell cycle genes and a component of the molecular prognostic score (mPS)...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27756880/lyn-expression-predicts-the-response-to-dasatinib-in-a-subpopulation-of-lung-adenocarcinoma-patients
#18
Yu Jin Kim, Sungyoul Hong, Minjung Sung, Min Jeong Park, Kyungsoo Jung, Ka-Won Noh, Doo-Yi Oh, Mi-Sook Lee, Ensel Oh, Young Kee Shin, Yoon-La Choi
Therapies targeting SRC family kinases (SFKs) have shown efficacy in treating non-small cell lung cancer (NSCLC). However, recent clinical trials have found that the SFK inhibitor dasatinib is ineffective in some patient cohorts. Regardless, dasatinib treatment may benefit some NSCLC patient subgroups. Here, we investigated whether expression of LYN, a member of the SFK family, is associated with patient survival, the efficacy of dasatinib, and/or NSCLC cell viability. LYN expression was associated with poor overall survival in a multivariate analysis, and this association was strongest in non-smoker female patients with adenocarcinoma (ADC)...
October 14, 2016: Oncotarget
https://www.readbyqxmd.com/read/27746955/a-novel-prognostic-marker-of-non-small-cell-lung-cancer-chromosome-9-open-reading-frame-86-c9orf86
#19
COMMENT
Katsuhiro Yoshimura, Murat Osman, Yusuke Inoue, Takafumi Suda, Haruhiko Sugimura
No abstract text is available yet for this article.
September 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27739521/label-free-enumeration-collection-and-downstream-cytological-and-cytogenetic-analysis-of-circulating-tumor-cells
#20
Manjima Dhar, Edward Pao, Corinne Renier, Derek E Go, James Che, Rosita Montoya, Rachel Conrad, Melissa Matsumoto, Kyra Heirich, Melanie Triboulet, Jianyu Rao, Stefanie S Jeffrey, Edward B Garon, Jonathan Goldman, Nagesh P Rao, Rajan Kulkarni, Elodie Sollier-Christen, Dino Di Carlo
Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement...
October 14, 2016: Scientific Reports
keyword
keyword
80881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"